140 related articles for article (PubMed ID: 32336971)
1. Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma.
Alsaud A; Mohamed S; Yassin MA; Ashour A; Obeidat K; Azrieh B
Case Rep Oncol; 2020; 13(1):207-211. PubMed ID: 32336971
[TBL] [Abstract][Full Text] [Related]
2. Chronic Myeloid Leukemia following Exposure to Radioactive Iodine (I131): A Systematic Review.
Ali Hailan YM; Al-Dubai HN; Yassin MA
Oncology; 2023; 101(6):362-368. PubMed ID: 37231874
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia following radioactive iodine therapy for papillary carcinoma of the thyroid.
Ankit J; S PC; S SK; P BP; V SK; Singh T; Batra U; Govind B; Dasappa L; Atilli S; R P
Turk J Haematol; 2009 Jun; 26(2):97-9. PubMed ID: 27265281
[TBL] [Abstract][Full Text] [Related]
4. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.
Kruijff S; Aniss AM; Chen P; Sidhu SB; Delbridge LW; Robinson B; Clifton-Bligh RJ; Roach P; Gill AJ; Learoyd D; Sywak MS
Surgery; 2013 Dec; 154(6):1337-44; discussion 1344-5. PubMed ID: 24383104
[TBL] [Abstract][Full Text] [Related]
5. Acute Myeloid Leukemia following Radioactive Iodine Therapy for Metastatic Follicular Carcinoma of the Thyroid.
Bishnoi K; Emerson R; Parida GK; Acharya P; Padhi S; Agrawal K
Indian J Nucl Med; 2023; 38(1):56-58. PubMed ID: 37180180
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy.
Jin M; Ahn J; Lee YM; Sung TY; Kim WG; Kim TY; Ryu JS; Kim WB; Shong YK; Jeon MJ
Endocrinol Metab (Seoul); 2020 Sep; 35(3):602-609. PubMed ID: 32981302
[TBL] [Abstract][Full Text] [Related]
7. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
[TBL] [Abstract][Full Text] [Related]
8. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
Suman P; Wang CH; Abadin SS; Block R; Raghavan V; Moo-Young TA; Prinz RA; Winchester DJ
Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
[TBL] [Abstract][Full Text] [Related]
9. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.
Molenaar RJ; Sidana S; Radivoyevitch T; Advani AS; Gerds AT; Carraway HE; Angelini D; Kalaycio M; Nazha A; Adelstein DJ; Nasr C; Maciejewski JP; Majhail NS; Sekeres MA; Mukherjee S
J Clin Oncol; 2018 Jun; 36(18):1831-1839. PubMed ID: 29252123
[TBL] [Abstract][Full Text] [Related]
10. Therapy-related acute myeloid leukemia following radioactive iodine treatment for thyroid cancer.
Oluwasanjo A; Pathak R; Ukaigwe A; Alese O
Cancer Causes Control; 2016 Jan; 27(1):143-6. PubMed ID: 26453198
[TBL] [Abstract][Full Text] [Related]
11. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
12. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
13. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
14. Second Primary Malignancy After Radioiodine Therapy in Thyroid Cancer Patient: A Nationwide Study.
Hong CM; Son J; Hyun MK; Lee JW; Lee J
Nucl Med Mol Imaging; 2023 Dec; 57(6):275-286. PubMed ID: 37982105
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.
Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P
Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663
[No Abstract] [Full Text] [Related]
16. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
[TBL] [Abstract][Full Text] [Related]
17. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
Jafri S; Yaqub A
Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
[TBL] [Abstract][Full Text] [Related]
18. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
19. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
[TBL] [Abstract][Full Text] [Related]
20. Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.
Zhao H; Gong Y
Front Endocrinol (Lausanne); 2022; 13():960682. PubMed ID: 36034423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
